One of these days a big RNS will drop and it'll explode into life. Totally agree GLR, those in the know taking positions prior to this occurring and the herd arriving.
Ref the Subway deal, they are still fulfilling some contractual obligations from the original contract that weren't able to be done because of Covid. Confident a renewal is on the cards, especially after Subway responded to me on Twitter to 'watch this space' ref a renewal.
The hedge is set at 43p a therm for 1.46m therms a month. They will be producing 1.54m therms month in the coming days. So that's £627k rev from the hedge and £320k rev from unhedged production (for now). Once the second compressor comes online it's all market rates which could happen in the next couple of months as they're currently not utilising the full flow rates of the two current wells. If they can take advantage of the full flow rates then they could generate an extra 30k therms daily which would equate to around £3m a month at today's prices. Plus looking further ahead they have the sidetrack that could double production again.
Thanks Charlie.
Other than the annual results on 30th, why do we think all the other news will land in March?
Definitely not worth reading much into. Simple fact remains that all the signs are that AVA6k is working and we await an official update to tell us that, which is due. If it's working, they either licence it for a big upfront fee for non dilutive funding (the plan all along), or they raise at a considerably higher SP than today to be able to fund the pipeline past mid 2023. Either option is good news. All this obviously depends on a good AVA update.
Here's the update doc. No mention of trading update. https://docs.google.com/forms/d/e/1FAIpQLScPO1DbwWepLBCNhlPpiq1_jnaMGYwqzaXD-k_ZmvIft0dBMQ/viewform
Have you only just realised this? That's why when the derampers drip on about needing funding through a placing it is highly unlikely if AVA6000 initial results are good. Not impossible, because it might be they can't secure a large up front licensing deal, but when P1a is complete in Q2 they will know whether it reduces/gets rids of side effects and if it does, that part of the platform is proven and at that point large pharma will know of the huge commercial opportunity and will likely want to be in on the action. Hence either a licensing deal or early moves for a takeover. If the LFT is not going to get us much (or any) revenue then the P1a data is absolutely pivotal.
Ndn, you clearly weren't listening. He said they continue to test negatives to drive thr decimal point. It's only negatives that they lack for the new govt requirements. Govt deal is still very much on the cards.
No one cares about ODX and their Visitect (Mologic) test. It could only detect 98% of positives with a CT of under 20 - that's poor. ODX are just waiting to be told to make our test. This just confirms (again) that the gov test isn't Mologic as they would have been making it by now. Not long now boys and girls.
There really isn't much more to discuss here. The affimer platform is completely derisked. The LFT WILL bring in enough revenue to fund the company going forward. News on manufacturers, licensing, UK (or other national Gov) contracts, takeover interest, NASDAQ listing, or any number of left field deals could literally land any day. If you don't need the money you have invested here right now then just sit tight. The derampers are scraping the barrell now and it's pretty pathetic. Can we start talking about therapeutics now because that's much more exciting!
There's been shed loads of publicity about how rubbish they are hants. Everyone I know talks about how LFTs aren't very accurate. Avacta are about to change the game though so not an issue, plus gov will buy them anyway.